Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients

被引:219
作者
Xenidis, Nikos
Perraki, Maria
Kafousi, Maria
Apostolaki, Stella
Bolonaki, Irene
Stathopoulou, Aliki
Kalbakis, Kostas
Androulakis, Nikos
Kouroussis, Charalambos
Pallis, Thanos
Christophylakis, Charalambos
Argyraki, Katerina
Lianidou, Evi S.
Stathopoulos, Stathis
Georgoulias, Vassilis
Mavroudis, Dimitris
机构
[1] Univ Gen Hosp Heraklion, Dept Med Oncol Pathol, Iraklion 71110, Crete, Greece
[2] Univ Crete, Sch Med, Tumor Cell Biol Lab, Iraklion, Crete, Greece
[3] Univ Athens, Fac Chem, Analyt Chem Lab, Athens, Greece
关键词
D O I
10.1200/JCO.2005.04.5948
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To evaluate the predictive and prognostic value Of peripheral blood cytokeratin-19 (CK-19) mRNA-positive cells in axillary lymph node-negative breast cancer patients. Patients and Methods Peripheral blood was obtained from 167 node-negative breast cancer patients before the initiation of any systemic adjuvant therapy, and Was analyzed for the presence of CK-19 mRNA-positive cells using a real time polymerase Chain reaction assay. The association with known prognostic factors and the effect of CK-19 mRNA-positive cells on patients' prognosis was investigated. Results CK-19 mRNA-positive cells were detected in the blood of 36 (21.6%) of the 167 patients. There was no correlation between the detection of CK-19 mRNA-positive cells in the peripheral blood and the various known pathologic and clinical prognostic factors; only overexpression of HER2 receptor (score 2+/3+) on the primary tumor was associated with a higher incidence of CK-19 mRNA-positive cell detection (P = .033). Multivariate analysis revealed that detection of peripheral blood CK-19 mRNA-positive cells was associated with early clinical relapse (P < .00001) and disease-related death (P = .008). Conclusion Detection of peripheral-blood CK-19 mRNA-positive cells is an independent predictive and prognostic factor for reduced disease-free interval and overall survival, respectively, in node-negative breast cancer patients.
引用
收藏
页码:3756 / 3762
页数:7
相关论文
共 35 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]  
Abe O, 1998, LANCET, V352, P930
[3]  
Altman DG, 1990, PRACTICAL STAT MED R
[4]  
Armitage P., 2001, STAT METHODS MED RES, V4th
[5]  
Bernard PS, 2002, CLIN CHEM, V48, P1178
[6]  
Bland KI, 1998, CANCER-AM CANCER SOC, V83, P1262, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1262::AID-CNCR28>3.0.CO
[7]  
2-2
[8]  
Bosma AJ, 2002, CLIN CANCER RES, V8, P1871
[9]   Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer [J].
Bozionellou, V ;
Mavroudis, D ;
Perraki, M ;
Papadopotilos, S ;
Apostolaki, S ;
Stathopoulos, E ;
Stathopoulou, A ;
Lianidou, E ;
Georgoulias, V .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8185-8194
[10]   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533